CY1114022T1 - Φαρμακα με δραση υποδοχεα ημ74α - Google Patents
Φαρμακα με δραση υποδοχεα ημ74αInfo
- Publication number
- CY1114022T1 CY1114022T1 CY20131100430T CY131100430T CY1114022T1 CY 1114022 T1 CY1114022 T1 CY 1114022T1 CY 20131100430 T CY20131100430 T CY 20131100430T CY 131100430 T CY131100430 T CY 131100430T CY 1114022 T1 CY1114022 T1 CY 1114022T1
- Authority
- CY
- Cyprus
- Prior art keywords
- alkyl
- medications
- hm74a receptor
- alkenyl
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
Abstract
Η παρούσα εφεύρεση παρέχει θεραπευτικώς δραστικές ενώσεις που είναι παράγωγα ξανθίνης, διεργασίες για την κατασκευή των προαναφερθέντων παραγώγων, φαρμακευτικές μορφοποιήσεις που περιέχουν τις δραστικές ενώσεις και τη χρήση των ενώσεων στη θεραπεία, ιδιαίτερα στην αντιμετώπιση νόσων όπου η υπο-ενεργοποίηση του υποδοχέα ΗΜ74Α συμβάλει στη νόσο ή όπου η ενεργοποίηση του υποδοχέα θα είναι ωφέλιμη, που έχει τον τύπο (II): όπου το R1 επιλέγεται από: υδρογόνο και C1-4 αλκύλιο το οποίο μπορεί να είναι προαιρετικά υποκατεστημένο με μία ή περισσότερες ομάδες που επιλέγονται από CN και CF3, το R2 επιλέγεται από C2-10 μη-υποκατεστημένο αλκύλιο, C1-10 αλκύλιο υποκατεστημένο με μία ή περισσότερες ομάδες που επιλέγονται από φθόριο και CN, C5 αλκενύλιο, μη-διακλαδωμένο C4 αλκενύλιο, και C1-4 αλκύλιο υποκατεστημένο με κυκλοαλκύλιο, και το R3 επιλέγεται από αλογόνο και CN.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0403282A GB0403282D0 (en) | 2004-02-14 | 2004-02-14 | Chemical compounds |
GB0423562A GB0423562D0 (en) | 2004-10-22 | 2004-10-22 | Novel compounds |
GB0428375A GB0428375D0 (en) | 2004-12-24 | 2004-12-24 | Novel compounds |
EP05707363A EP1781657B1 (en) | 2004-02-14 | 2005-02-10 | Medicaments with hm74a receptor activity |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114022T1 true CY1114022T1 (el) | 2016-07-27 |
Family
ID=34864831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100430T CY1114022T1 (el) | 2004-02-14 | 2013-05-29 | Φαρμακα με δραση υποδοχεα ημ74α |
Country Status (26)
Country | Link |
---|---|
US (5) | US7713982B2 (el) |
EP (1) | EP1781657B1 (el) |
JP (2) | JP5001012B2 (el) |
KR (1) | KR101100601B1 (el) |
CN (2) | CN101103030B (el) |
AR (1) | AR047669A1 (el) |
AU (1) | AU2005212816C1 (el) |
BR (1) | BRPI0507604A (el) |
CA (1) | CA2556073C (el) |
CY (1) | CY1114022T1 (el) |
DK (1) | DK1781657T3 (el) |
ES (1) | ES2406732T3 (el) |
HK (1) | HK1104530A1 (el) |
HR (1) | HRP20130406T1 (el) |
IL (1) | IL177051A (el) |
MA (1) | MA28357A1 (el) |
MY (1) | MY148937A (el) |
NO (1) | NO337281B1 (el) |
NZ (1) | NZ548496A (el) |
PE (1) | PE20060317A1 (el) |
PL (1) | PL1781657T3 (el) |
PT (1) | PT1781657E (el) |
SG (1) | SG157242A1 (el) |
SI (1) | SI1781657T1 (el) |
TW (1) | TWI350289B (el) |
WO (1) | WO2005077950A2 (el) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60041710D1 (de) * | 1999-11-12 | 2009-04-16 | Biogen Idec Inc | Polycycloalkylpurine als adenosinrezeptorantagonisten |
AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
TWI258478B (en) | 2003-10-31 | 2006-07-21 | Arena Pharm Inc | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
KR101100601B1 (ko) * | 2004-02-14 | 2011-12-29 | 글락소스미스클라인 엘엘씨 | 신규 화합물 |
CN102633730A (zh) | 2004-12-03 | 2012-08-15 | 先灵公司 | 作为cb1拮抗剂的取代哌嗪 |
MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
US7750015B2 (en) | 2005-05-17 | 2010-07-06 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
BRPI0610133A2 (pt) | 2005-05-17 | 2010-06-01 | Schering Corp | heterociclos como agonistas de receptor de ácido nicotìnico para o tratamento de dislipidemia |
KR100955112B1 (ko) | 2005-06-14 | 2010-04-28 | 에프. 호프만-라 로슈 아게 | 안트라닐산 유도체 |
CA2611552A1 (en) | 2005-06-28 | 2007-01-04 | Merck & Co., Inc. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
JP2009504592A (ja) * | 2005-08-10 | 2009-02-05 | スミスクライン・ビーチャム・コーポレイション | 選択的hm74aアゴニストとしてのキサンチン誘導体 |
EP1976854A2 (en) * | 2006-01-20 | 2008-10-08 | Shering Corporation | Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia |
DE602007006947D1 (de) * | 2006-05-23 | 2010-07-15 | Hoffmann La Roche | Pyridopyrimidinonderivate |
TW200804383A (en) * | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
JP5274455B2 (ja) | 2006-06-23 | 2013-08-28 | インサイト コーポレイション | Hm74aアゴニストとしてのプリノン誘導体 |
TWI423977B (zh) * | 2006-06-23 | 2014-01-21 | Incyte Corp | 作為hm74a同效劑之嘌呤酮衍生物(一) |
JP2010521513A (ja) | 2007-03-23 | 2010-06-24 | エフ.ホフマン−ラ ロシュ アーゲー | アザ−ピリドピリミジノン誘導体 |
AU2009324811B2 (en) | 2008-12-08 | 2013-01-24 | Glaxosmithkline Llc | Novel compounds |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
CN102276610B (zh) * | 2011-05-04 | 2013-01-09 | 北京工业大学 | N7-鸟嘌呤烷化物的制备方法 |
CN103360394B (zh) * | 2013-07-29 | 2015-07-22 | 上海万巷制药有限公司 | 8-氯茶碱的制备方法 |
US10322132B2 (en) * | 2015-01-30 | 2019-06-18 | Shanton Pharma Co., Ltd | Prevention or treatment of uratic or gouty diseases |
CN104892610B (zh) * | 2015-05-27 | 2016-08-24 | 福建师范大学 | 一种8-酯基咖啡因衍生物的制备方法 |
CN105622610A (zh) * | 2016-03-28 | 2016-06-01 | 浙江诚意药业股份有限公司 | 一种黄嘌呤化合物的制备方法 |
CA3032229A1 (en) | 2016-07-27 | 2018-02-01 | Hartis-Pharma Sa | Therapeutic combinations to treat red blood cell disorders |
CN106632061B (zh) * | 2016-11-23 | 2020-07-24 | 上海皓元医药股份有限公司 | 一种1-(4-苯基-1-烷基-1h-咪唑-2-基)乙酮及其衍生物的合成方法 |
UY37557A (es) | 2017-01-10 | 2018-07-31 | Bayer Ag | Derivados heterocíclicos como pesticidas |
JP2022549807A (ja) * | 2019-09-25 | 2022-11-29 | ゴールドフィンチ バイオ,インク. | キサンチンcb1阻害物質 |
CN112724141A (zh) * | 2021-01-21 | 2021-04-30 | 南京艾美斐生物医药科技有限公司 | 一种gpr109a蛋白受体抑制剂及其制备和应用 |
CN113262882B (zh) * | 2021-07-21 | 2021-09-17 | 北京矿冶研究总院 | 阳离子捕收剂、制备方法及在磷矿反浮选中的应用 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2797220A (en) * | 1954-12-02 | 1957-06-25 | Univ Michigan | Substituted paraxanthines |
US4847377A (en) * | 1985-05-13 | 1989-07-11 | Schering Corporation | Substituted-2,3-dihydro-6-substituted-pyrimido[2,1-F]-purine-4,8(1H,9H)-diones |
GB8906792D0 (en) * | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
NZ240644A (en) * | 1990-11-21 | 1994-08-26 | Smithkline Beecham Corp | Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf) |
AU3725893A (en) * | 1992-02-21 | 1993-09-13 | Smithkline Beecham Corporation | TNF inhibitors |
DE69332634T2 (de) | 1992-03-04 | 2003-05-08 | Cell Therapeutics Inc | Enantiomere hydroxylierte xanthinverbindungen |
US5804584A (en) | 1992-11-16 | 1998-09-08 | Cell Therapeutics, Inc. | Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms |
US6693105B1 (en) | 1992-11-16 | 2004-02-17 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
US5473070A (en) | 1992-11-16 | 1995-12-05 | Cell Therapeutics, Inc. | Substituted long chain alcohol xanthine compounds |
US6469017B1 (en) | 1998-01-16 | 2002-10-22 | Cell Therapeutics, Inc. | Method of inhibiting interleukin-12 signaling |
IL109161A0 (en) | 1993-03-31 | 1994-06-24 | Cell Therapeutics Inc | Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same |
US5670506A (en) | 1993-04-05 | 1997-09-23 | Cell Therapeutics, Inc. | Halogen, isothiocyanate or azide substituted xanthines |
WO1994024133A1 (en) | 1993-04-09 | 1994-10-27 | Cell Therapeutics, Inc. | Ring-substituted cell signaling inhibitors |
WO1995020589A1 (en) | 1994-01-28 | 1995-08-03 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
US6878715B1 (en) | 1994-02-18 | 2005-04-12 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same |
WO1995022546A1 (en) | 1994-02-18 | 1995-08-24 | Cell Therapeutics, Inc. | Intracellular signalling mediators |
US6103730A (en) | 1994-03-24 | 2000-08-15 | Cell Therapeutics, Inc. | Amine substituted compounds |
US6780865B1 (en) | 1994-02-18 | 2004-08-24 | Cell Therapeutics, Inc. | Compounds having selective hydrolytic potentials |
US5807861A (en) | 1994-03-24 | 1998-09-15 | Cell Therapeutics, Inc. | Amine substituted xanthinyl compounds |
US5801182A (en) | 1994-03-24 | 1998-09-01 | Cell Therapeutics, Inc. | Amine substituted compounds |
US6323201B1 (en) | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
AR015966A1 (es) * | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
MXPA01010143A (es) | 1999-04-09 | 2003-07-14 | Cell Therapeutics Inc | Derivados de xantina y analogos como inhibidores de transmision de senales celulares. |
US20030207901A1 (en) | 1999-07-27 | 2003-11-06 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
BR0013673A (pt) * | 1999-08-31 | 2002-05-28 | Univ Vanderbilt | Antagonistas seletivos de receptores de adenosina a2b |
US6855817B2 (en) * | 2000-07-21 | 2005-02-15 | Mark B. Lyles | Materials and methods for binding nucleic acids to surfaces |
FR2812482B1 (fr) * | 2000-07-28 | 2003-01-24 | Inside Technologies | Dispositif electronique portable comprenant plusieurs circuits integres sans contact |
JP2004512278A (ja) * | 2000-09-19 | 2004-04-22 | ノビムーヌ ソシエテ アノニム | 新規な免疫調節剤、免疫阻害剤、及び抗炎症剤としてのスタチン(HMG−CoAリダクターゼ阻害剤) |
US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
DK1953162T3 (da) | 2001-02-24 | 2012-09-10 | Boehringer Ingelheim Pharma | Xanthinderivater, deres fremstilling og deres anvendelse som lægemiddel. |
WO2002084298A2 (en) * | 2001-04-11 | 2002-10-24 | Glaxo Group Limited | Medicaments which are modulators of hm74 and/or hm74a activity |
KR101100601B1 (ko) * | 2004-02-14 | 2011-12-29 | 글락소스미스클라인 엘엘씨 | 신규 화합물 |
US20090209561A1 (en) | 2004-10-22 | 2009-08-20 | Richard Jonathan Daniel Hatley | Xanthine Derivatives with HM74A Receptor Activity |
WO2006045564A1 (en) | 2004-10-22 | 2006-05-04 | Smithkline Beecham Corporation | Xanthine derivatives with hm74a receptor activity |
JP2009504592A (ja) | 2005-08-10 | 2009-02-05 | スミスクライン・ビーチャム・コーポレイション | 選択的hm74aアゴニストとしてのキサンチン誘導体 |
EP1939197A1 (en) * | 2006-12-22 | 2008-07-02 | Schwarz Pharma Ag | 8-ethinylxanthine derivatives as selective A2A receptor antagonists |
AU2009324811B2 (en) * | 2008-12-08 | 2013-01-24 | Glaxosmithkline Llc | Novel compounds |
US20110065676A1 (en) * | 2009-06-24 | 2011-03-17 | Schering Corporation | Combination therapies comprising par1 antagonists with nar agonists |
-
2005
- 2005-02-10 KR KR1020067016277A patent/KR101100601B1/ko active IP Right Grant
- 2005-02-10 SI SI200531730T patent/SI1781657T1/sl unknown
- 2005-02-10 WO PCT/EP2005/001449 patent/WO2005077950A2/en active Application Filing
- 2005-02-10 EP EP05707363A patent/EP1781657B1/en active Active
- 2005-02-10 AU AU2005212816A patent/AU2005212816C1/en not_active Ceased
- 2005-02-10 PT PT57073637T patent/PT1781657E/pt unknown
- 2005-02-10 JP JP2006552565A patent/JP5001012B2/ja not_active Expired - Fee Related
- 2005-02-10 ES ES05707363T patent/ES2406732T3/es active Active
- 2005-02-10 DK DK05707363.7T patent/DK1781657T3/da active
- 2005-02-10 CN CN2005800114336A patent/CN101103030B/zh not_active Expired - Fee Related
- 2005-02-10 CA CA2556073A patent/CA2556073C/en not_active Expired - Fee Related
- 2005-02-10 US US10/589,474 patent/US7713982B2/en not_active Expired - Fee Related
- 2005-02-10 BR BRPI0507604-8A patent/BRPI0507604A/pt not_active Application Discontinuation
- 2005-02-10 PL PL05707363T patent/PL1781657T3/pl unknown
- 2005-02-10 CN CN2010102007350A patent/CN101863888B/zh not_active Expired - Fee Related
- 2005-02-10 SG SG200803771-5A patent/SG157242A1/en unknown
- 2005-02-10 NZ NZ548496A patent/NZ548496A/en not_active IP Right Cessation
- 2005-02-11 PE PE2005000170A patent/PE20060317A1/es not_active Application Discontinuation
- 2005-02-14 MY MYPI20050527A patent/MY148937A/en unknown
- 2005-02-14 AR ARP050100512A patent/AR047669A1/es not_active Application Discontinuation
- 2005-02-14 TW TW094104133A patent/TWI350289B/zh not_active IP Right Cessation
-
2006
- 2006-07-24 IL IL177051A patent/IL177051A/en not_active IP Right Cessation
- 2006-08-11 MA MA29262A patent/MA28357A1/fr unknown
- 2006-09-13 NO NO20064151A patent/NO337281B1/no not_active IP Right Cessation
-
2007
- 2007-09-04 HK HK07109621.1A patent/HK1104530A1/xx not_active IP Right Cessation
-
2008
- 2008-02-12 JP JP2008030344A patent/JP5020848B2/ja not_active Expired - Fee Related
-
2009
- 2009-09-02 US US12/552,649 patent/US8394808B2/en not_active Expired - Fee Related
-
2010
- 2010-03-04 US US12/717,349 patent/US8268839B2/en not_active Expired - Fee Related
-
2013
- 2013-02-06 US US13/760,423 patent/US20130150383A1/en not_active Abandoned
- 2013-05-08 HR HRP20130406TT patent/HRP20130406T1/hr unknown
- 2013-05-29 CY CY20131100430T patent/CY1114022T1/el unknown
-
2014
- 2014-11-21 US US14/549,721 patent/US20150080418A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1114022T1 (el) | Φαρμακα με δραση υποδοχεα ημ74α | |
CY1111757T1 (el) | Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α | |
CY1122336T1 (el) | Eνωσεις πυρρολιου ως αναστολεις πρωτεϊνικων κινασων εrκ και φαρμακευτικες συνθεσεις που περιεχουν αυτες τις ενωσεις | |
CY1117217T1 (el) | Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξοοξικης πιπεραζινης | |
CY1110965T1 (el) | Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου | |
CY1110058T1 (el) | Πυριμιδινες υποκατεστημενες με σουλφοξιμινη ως αναστολεις cdk και/ή vegf, η παρασκευη τους και η χρηση τους ως φαρμακευτικα μεσα | |
CY1110177T1 (el) | Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης | |
CY1106933T1 (el) | Ενωσεις πυριμιδινης | |
ECSP055640A (es) | Composiciones de pirazol útiles como inhibidores de gsk-3 | |
GT200100183A (es) | Derivados de quinolina y quinazolina. | |
CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
ECSP055899A (es) | Pirimidinas inhibidoras de chk, pdk y akt, su producción y su uso como agentes farmacéuticos | |
CY1107244T1 (el) | Μιμητικα γλυκοκορτικοειδων, μεθοδοι παρασκευης τους, φαρμακευτικες συνθεσεις και χρησεις τους | |
CY1106476T1 (el) | Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες | |
CY1113736T1 (el) | Ετεροαρυλ-ουριες και η χρηση τους ως ενεργοποιητες γλυκοκινασης | |
DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
CY1110583T1 (el) | Παραγωγα ν4-φαινυλ-κιναζολινο-4-αμινης και σχετικες ενωσεις ως αναστολεις υποδοχεα κινασης τυροσινης τυπου i erbb για τη θεραπεια υπερπολλαπλασιαστικων ασθενειων | |
CY1115289T1 (el) | Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη | |
CY1108813T1 (el) | Αναστολεις κινασων τυροσινης | |
BRPI0413452A (pt) | composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv | |
CY1108067T1 (el) | Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης | |
CY1112402T1 (el) | Ενισχυτες υποδοχεων γλουταμικου | |
CY1108267T1 (el) | Ενωσεις που επηρεαζουν τη γλυκοκιναση | |
CY1110419T1 (el) | Τρικυκλικες ενωσεις με βαση το 1,6-διυδρο-1,3,5,6-tetpaaza-as-ινδακενιο και φαρμακευτικες συνθεσεις που τις περιεχουν ως αναστολεις της ενζυμικης ενεργοτητας της ικκ | |
CY1108378T1 (el) | 4-υποκατεστημενα παραγωγα 1-αμινοκυκλοεξανιου για την χρησιμοποιηση σαν προσδεματα υποδοχεα orl1 ή οπιακου υποδοχεα mu |